110 related articles for article (PubMed ID: 12192235)
1. Statins and cancer: will we ever know the answer?
Etminan M; Coogan PF; Rosenberg L
Epidemiology; 2002 Sep; 13(5):607; author reply 607-8. PubMed ID: 12192235
[No Abstract] [Full Text] [Related]
2. Lipid lowering, statins and cancer.
Wierzbicki AS
Int J Clin Pract; 2006 Sep; 60(9):1022-4. PubMed ID: 16939539
[No Abstract] [Full Text] [Related]
3. Statins and cancer development.
Duncan RE; El-Sohemy A; Archer MC
Cancer Epidemiol Biomarkers Prev; 2005 Aug; 14(8):1897-8. PubMed ID: 16103434
[TBL] [Abstract][Full Text] [Related]
4. Complications and side effects. Concerns about statins.
TreatmentUpdate; 2005; 17(4):5-6. PubMed ID: 17228472
[No Abstract] [Full Text] [Related]
5. Statins and natural regulatory T cells in HIV infection.
Mascitelli L; Pezzetta F; Goldstein MR
HIV Med; 2008 Feb; 9(2):131. PubMed ID: 18257776
[No Abstract] [Full Text] [Related]
6. The risk of myopathy associated with thiazolidinediones and statins in patients with type 2 diabetes: a nested case-control analysis.
Koro CE; Sowell MO; Stender M; Qizilbash N
Clin Ther; 2008 Mar; 30(3):535-42. PubMed ID: 18405791
[TBL] [Abstract][Full Text] [Related]
7. [Myopathy with rhabdomyolysis as an adverse effect of simultaneous treatment with cerivastatin and gemfibrozil].
Huić M; Anić B; Cikes N; Bosnić D; Sentić M; Markeljević J; Mayer M; Pazanin L
Lijec Vjesn; 2002; 124(3-4):73-6. PubMed ID: 18956824
[TBL] [Abstract][Full Text] [Related]
8. Side effects of statins--prevalence, relevance, consequences.
Sinzinger H
Wien Klin Wochenschr; 2002 Nov; 114(21-22):887-8. PubMed ID: 12528318
[No Abstract] [Full Text] [Related]
9. Experts confirm statins' safety but advise caution with certain patients.
Levenson D
Rep Med Guidel Outcomes Res; 2002 Jul; 13(13):1-2, 5. PubMed ID: 12515256
[No Abstract] [Full Text] [Related]
10. Lipid-lowering therapy--benefits and risks.
Abinader EG
Isr Med Assoc J; 2007 Feb; 9(2):132-3; author reply 133-4. PubMed ID: 17354321
[No Abstract] [Full Text] [Related]
11. Statins and cancer.
Harv Mens Health Watch; 2007 Nov; 12(4):6-8. PubMed ID: 18217256
[No Abstract] [Full Text] [Related]
12. Lipid-lowering therapy--benefits and risks.
Shechter M
Isr Med Assoc J; 2007 Feb; 9(2):133; author reply 133-4. PubMed ID: 17348492
[No Abstract] [Full Text] [Related]
13. Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis.
Matzno S; Tazuya-Murayama K; Tanaka H; Yasuda S; Mishima M; Uchida T; Nakabayashi T; Matsuyama K
J Pharm Pharmacol; 2003 Jun; 55(6):795-802. PubMed ID: 12841940
[TBL] [Abstract][Full Text] [Related]
14. Intensive lipid-lowering therapy: obvious benefits, possible risks.
Zimlichman E; Szyper-Kravitz M; Katz U; Shoenfeld Y
Isr Med Assoc J; 2006 Dec; 8(12):890-1. PubMed ID: 17214117
[No Abstract] [Full Text] [Related]
15. Common obstacles in lipid management.
Elpers M
Crit Care Nurs Clin North Am; 2008 Sep; 20(3):287-95. PubMed ID: 18644511
[TBL] [Abstract][Full Text] [Related]
16. Statins and the risk of lung, breast, and colorectal cancer in the elderly.
Setoguchi S; Glynn RJ; Avorn J; Mogun H; Schneeweiss S
Circulation; 2007 Jan; 115(1):27-33. PubMed ID: 17179016
[TBL] [Abstract][Full Text] [Related]
17. Myopathy caused by a combination rosuvastatin and fenofibrate.
Dedhia V; Munsi SC
J Assoc Physicians India; 2007 Feb; 55():152-3. PubMed ID: 17571748
[No Abstract] [Full Text] [Related]
18. Rhabdomyolysis from the combination of a statin and gemfibrozil: an uncommon but serious adverse reaction.
Kind AH; Zakowski LJ; McBride PE
WMJ; 2002; 101(7):53-6. PubMed ID: 12426921
[TBL] [Abstract][Full Text] [Related]
19. Re: Dyslipidemia is a protective factor in amyotrophic lateral sclerosis.
Yoshii Y; Ikeda K; Iwamoto K; Kawase Y; Iwasaki Y
Neurology; 2009 Mar; 72(10):944; author reply 944-5. PubMed ID: 19273834
[No Abstract] [Full Text] [Related]
20. Complications and side effects. Crestor tested in PHAs.
TreatmentUpdate; 2005; 17(4):6-7. PubMed ID: 17230630
[No Abstract] [Full Text] [Related]
[Next] [New Search]
